Zentalis Pharmaceuticals, Inc. financial data

Symbol
ZNTL on Nasdaq
Industry
Pharmaceutical Preparations
Location
10275 Science Center Drive, Suite 200, San Diego, California
Fiscal year end
December 31
Former names
Zentalis Pharmaceuticals, LLC (to 4/6/2020), Zeno Pharma, LLC (to 9/5/2019)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 788 % -7.28%
Debt-to-equity 24.2 % +5.13%
Return On Equity -44.2 % +31.3%
Return On Assets -35.6 % +32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.1M shares +0.71%
Common Stock, Shares, Outstanding 71.1M shares +0.71%
Entity Public Float 1.56B USD +20%
Common Stock, Value, Issued 71K USD +1.43%
Weighted Average Number of Shares Outstanding, Basic 71M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 71M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 196M USD +12.8%
General and Administrative Expense 64.8M USD +17.5%
Operating Income (Loss) -221M USD +19.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -238M USD -44.4%
Income Tax Expense (Benefit) 305K USD
Net Income (Loss) Attributable to Parent -195M USD +31.7%
Earnings Per Share, Basic -2.65 USD/shares +44.2%
Earnings Per Share, Diluted -2.65 USD/shares +44.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37M USD -86.1%
Assets, Current 440M USD -22%
Property, Plant and Equipment, Net 5.34M USD -19.7%
Operating Lease, Right-of-Use Asset 33.5M USD -8.5%
Goodwill 3.74M USD 0%
Assets 492M USD -20.9%
Accounts Payable, Current 20.4M USD +66.1%
Employee-related Liabilities, Current 6.47M USD -19%
Accrued Liabilities, Current 46.3M USD +17.2%
Liabilities, Current 66.7M USD +28.9%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 41.3M USD -6.15%
Other Liabilities, Noncurrent 1.09M USD -54.2%
Liabilities 109M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 140K USD
Retained Earnings (Accumulated Deficit) -967M USD -25.2%
Stockholders' Equity Attributable to Parent 383M USD -26.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 383M USD -26.9%
Liabilities and Equity 492M USD -20.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52M USD -5.46%
Net Cash Provided by (Used in) Financing Activities 373K USD -70.4%
Net Cash Provided by (Used in) Investing Activities 61.5M USD +46.1%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 71.1M shares +0.71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.58M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.7M USD -85.3%
Deferred Tax Assets, Valuation Allowance 219M USD +36.2%
Deferred Tax Assets, Gross 230M USD +31.2%
Operating Lease, Liability 44M USD -5.04%
Payments to Acquire Property, Plant, and Equipment 40K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -194M USD +31.6%
Lessee, Operating Lease, Liability, to be Paid 63.6M USD -9.15%
Property, Plant and Equipment, Gross 8.97M USD -4.69%
Operating Lease, Liability, Current 2.71M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.28M USD +7.05%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.8M USD +4.83%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19.6M USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.45M USD +2.38%
Deferred Tax Assets, Operating Loss Carryforwards 96.7M USD +1.35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.21M USD -1.93%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.76M USD +4.15%
Additional Paid in Capital 1.35B USD +4.14%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.34M USD -7.09%
Deferred Tax Assets, Net of Valuation Allowance 10.4M USD -26.6%
Share-based Payment Arrangement, Expense 53.3M USD +13.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%